Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIEVE: Granisetron vs Granisetron + ME2136 for PONV in Lung Resection Surgery
jRCT2041240130Phase 2Recruiting
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in postoperative nausea and vomiting (PONV) comparing Standard group: Granisetron alone with Treatment group: Granisetron + ME2136 (2 arms). Primary endpoint: Complete response within 24 hours after surgery. Started Jan 2025; status: recruiting.
02
Drugs
granisetronolanzapine
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on jRCT2041240130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041240130.